On July 25, 2025 BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, reported two clinical data poster presentations at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2025 Annual Meeting taking place October 17 – 21 in Berlin, Germany (Press release, BriaCell Therapeutics, JUL 25, 2025, View Source [SID1234655034]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The titles of the poster presentations are listed below.

#8212: Phase III Pivotal Trial of Bria-IMT + CPI vs Physician’s Choice in Advanced Metastatic Breast Cancer (BRIA-ABC)

#3928: Feasibility and Biomarker Validation of an International Randomized Phase 3 Trial of Bria-IMT Cell Therapy in Late Stage MBC (BRIA-ABC)

Abstracts will be published online via the ESMO (Free ESMO Whitepaper) website at 00:05 CEST on October 13 th 2025 (6:05 pm ET on October 12 th ).

Following the presentations, copies of the presentations will be posted on View Source